Earnings Conference Call Overview: VolitionRx Limited held its Q2 2025 earnings conference call on August 15, 2025, featuring key company executives discussing financial performance and future outlook.
Forward-Looking Statements Disclaimer: The call included a reminder about forward-looking statements that involve risks and uncertainties, with actual results potentially differing from those projected due to various factors.
VNRX
$0.2421+Infinity%1D
Analyst Views on VNRX
Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.244
Low
2.50
Averages
2.50
High
2.50
Current: 0.244
Low
2.50
Averages
2.50
High
2.50
Maxim
Buy
to
Hold
downgrade
2025-12-03
Reason
Maxim
Price Target
2025-12-03
downgrade
Buy
to
Hold
Reason
Maxim downgraded VolitionRx to Hold from Buy.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-11-17
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on VolitionRx (VNRX) to $1.50 from $2.50 and keeps a Buy rating on the shares. VolitionRx posted Q3 revenue that was up 32% year over year and a $5.4M net loss, while securing two notable human diagnostics agreements with Werfen and Hologic (HOLX), the analyst tells investors in a research note. With roughly 10 major diagnostics and liquid-biopsy companies engaged at various stages of partnership discussions, management expects additional licensing deals, underscoring the broad potential of the Nu.Q platform across cancer, sepsis, and epigenetic drug development, the firm says.
JonesResearch
Justin Walsh
Buy
initiated
$3
2025-06-09
Reason
JonesResearch
Justin Walsh
Price Target
$3
2025-06-09
initiated
Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$2.5
2025-04-11
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2.5
2025-04-11
Reiterates
Strong Buy
Reason
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
